Drug Trial Radar · NCT07755150
A Study to Evaluate the Efficacy and Safety of DA-302168S Tablets in Subjects With Type 2 Diabetes
Last checked: Nov 19, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
272
Planned (sponsor's estimate)
Start
Aug 30, 2026
Primary completion
Oct 20, 2027
Study completion Oct 20, 2027
Sponsor
- Lead sponsor
- Chendu DIAO Pharmaceutical Group CO., LTD.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study aims to assess the efficacy, safety, and PK characteristics of DA-302168S tablets in Chinese T2DM participants, and to provide dose-selection evidence for the Phase III confirmatory trial.
Conditions
- Type 2 Diabetes Mellitus
Interventions
DA-302168SDrug
A small molecule GLP-1R agonist tablet, orally administration, once daily,16weeks.
Placebo of DA-302168SDrug
Matching placebo tablet will be provided
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in HbA1cTime frame: From baseline (week 1) to week 16
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University People's Hospital
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.